Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged 18 years and older~* Systemic sclerosis, as defined by ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) 2013 criteria~* dcSSc (diffuse cutaneous systemic sclerosis) according to the LeRoy criteria, ie, skin fibrosis proximal to the elbows and knees in addition to acral fibrosis~* Disease duration of ≤ 18 months (defined as time from the first non-Raynaud's phenomenon manifestation)~* ≥ 10 and ≤ 22 mRSS (modified Rodnan skin score) units at the screening visit~* FVC (forced vital capacity) ≥ 45% of predicted at screening~* DLCO (diffusion capacity of the lung for carbon monoxide) ≥ 40% of predicted (hemoglobin-corrected) at screening~* Negative serum pregnancy test in a woman of childbearing potential at the screening visit~* Women of childbearing potential must agree to use adequate contraception when sexually active. Adequate contraception is defined as any combination of at least 2 effective methods of birth control, of which at least 1 is a physical barrier (e.g. condom with hormonal contraception like implants or combined oral contraceptives, condom with intrauterine devices). This applies since signing of the informed consent form until 30 (+5) days after the last study drug administration.~Exclusion Criteria:~* Limited cutaneous SSc (systemic sclerosis) at screening~* Major surgery (including joint surgery) within 8 weeks prior to screening~* Hepatic insufficiency classified as Child-Pugh C~* Patients with isolated AST or ALT \>3xULN or bilirubin \>2xULN can be included in the trial under the condition of additional monitoring during the trial~* Estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73 m\^2 (Modification of Diet in Renal Disease formula) or on dialysis at the screening visit. Patients entering the trial with eGFR 15-29 mL/min/1.73 m\^2 will be undergo additional monitoring of renal function~* Any prior history of renal crisis~* Sitting SBP (systolic blood pressure) \< 95 mmHg at the screening visit~* Sitting heart rate \< 50 beats per minute (BPM) at the screening visit~* Left ventricular ejection fraction \< 40% prior to screening~* Any form of pulmonary hypertension as determined by right heart catheterization~* Pulmonary disease with FVC \< 45% of predicted or DLCO (hemoglobin-corrected) \< 40% of predicted at screening~* Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization~* Not permitted prior and concomitant medication~* Pregnant or breast feeding women~* Women of childbearing potential not willing to use adequate contraception and not willing to agree to 4-weekly pregnancy testing from Visit 1 (first administration of study drug) onwards until 30 (+5) days after last study drug intake.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Riociguat (Type: EXPERIMENTAL): Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
- Placebo (Type: PLACEBO_COMPARATOR): Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.

Based on this trial design, predict the completion outcome and termination type (if applicable).